Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies

Next Previous
X
Search
Trial Profile

Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 30 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ieramilimab (Primary) ; Spartalizumab (Primary)
  • Indications Adenocarcinoma; Diffuse large B cell lymphoma; Gastric cancer; Haematological malignancies; Lymphoma; Neuroendocrine tumours; Oesophageal cancer; Ovarian cancer; Prostate cancer; Small cell lung cancer; Soft tissue sarcoma; Solid tumours
  • Focus Therapeutic Use
  • Acronyms Module 9
  • Sponsors Novartis Pharmaceuticals

    • Most Recent Events

    • 30 Sep 2020 Status changed from active, no longer recruiting to completed.
    • 31 Aug 2020 Number of treatment arms is reduced from 7 to 1 and Progression free survival is no longer a primary end-point but is moved to Secondary end-points. There are no Parallel cohorts for different tumours, but only one cohort for all the tumours.
    • 31 Aug 2020 Planned End Date changed from 19 Sep 2020 to 21 Sep 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top